MetaCap

AN2 Therapeutics Inc. (ANTX)

NASDAQ: ANTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

5.08-0.14 (-2.68%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ANTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$192.75M
EPS (TTM)
-$0.91
52-week range
1.00 – 7.19
Day range
4.99 – 5.49
Volume / Avg
332.67K / 289.29K
Beta
—

52-week range

$1.00$7.19

ANTX stock today

AN2 Therapeutics (ANTX) closed at $5.08 on Nov 20, down 2.68% (-$0.14), versus the S&P 500's 3.70% decline. Shares are 29.3% below their 52-week high of $7.19, set on Aug 12, 2026 and 408.0% above the 52-week low of $1.00, in the middle of the past year's range. ANTX is up 345.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 366.1%.

AN2 Therapeutics has posted a net loss over the last twelve months (EPS of -$0.91), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About AN2 Therapeutics

Company profile

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Eric E. Easom
Headquarters
Menlo Park, CA
Employees
21
IPO year
2022

Financial highlights

Full financials

AN2 Therapeutics reported a net loss of $35.2 million, compared with a loss of $51.3 million a year earlier. Diluted earnings per share came in at -$1.16.

AN2 Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-35.17M$-51.32M$-64.73M$-40.96M$-21.54M
EPS (diluted)$-1.16$-1.72$-2.74$-2.79$-10.64

Analyst forecast

Forecast

Consensus (2 analysts)

strong_buy

Avg. price target

$9.00+77.17%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.17 vs —

ANTX news

All ANTX news

AN2 Therapeutics peers

Health Care sector
ANTX peer companies
CompanyPrice% ChgMarket capCompare
ACIUAC Immune SA1.95-8.45%$193.88Mvs ANTX
YARWYarrow Bioscience Inc.12.90-9.35%$196.53Mvs ANTX
BIOABioAge Labs Inc.4.28-9.13%$196.67Mvs ANTX
RNACCartesian Therapeutics Inc.6.14+4.24%$187.29Mvs ANTX
NGENNervGen Pharma Corp.1.85-3.91%$198.55Mvs ANTX
DRUGBright Minds Biosciences Inc.20.40-1.45%$201.23Mvs ANTX
BCYCBicycle Therapeutics plc ADR2.90-4.92%$203.27Mvs ANTX
FTHFaeth Therapeutics Inc.7.88-9.32%$203.65Mvs ANTX

Indexes, lists and sector

AN2 Therapeutics stock FAQ

What is AN2 Therapeutics's stock price today?

ANTX last traded at $5.08 as of Nov 20, 4:00 PM EST, down 2.68% on the day. Prices are delayed at least 15 minutes.

Who is AN2 Therapeutics's CEO?

Mr. Eric E. Easom is the chief executive officer of AN2 Therapeutics Inc., which has about 21 employees.

What is the ANTX 52-week high?

The 52-week high for ANTX is $7.19 and the 52-week low is $1.00. The stock is currently 29.3% below its high.

Compare ANTX